Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Public ClinicalTrials.gov record NCT02792192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With or Without Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
Study identification
- NCT ID
- NCT02792192
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- Atezolizumab Drug
- Bacille Calmette-Guérin Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2016
- Primary completion
- Sep 28, 2020
- Completion
- Sep 28, 2020
- Last update posted
- Oct 27, 2021
2016 – 2020
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Univ. | Stanford | California | 94305 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Johns Hopkins Kimmel Cancer Center, Office of Research Administration | Baltimore | Maryland | 21205 | — |
| The Montefiore Medical Center & The Albert Einstein College of Medicine; Department of Urology | The Bronx | New York | 10461 | — |
| Duke University | Durham | North Carolina | 27705 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Oklahoma University Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| VA Portland Healthcare System | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02792192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2021 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02792192 live on ClinicalTrials.gov.